LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

Topline data expected in 1Q 2028Phase 2bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan.

LB Pharmaceuticals initiates Phase 2 trial of LB-102

Detailed price information for Lb Pharmaceuticals Inc (LBRX-Q) from The Globe and Mail including charting and trades.
Seeking Alpha

LB Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of LB-102 in Schizophrenia

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of psychiatric diseases including ...
Business Wire

Segal Trials Leads Phase 2 Schizophrenia Trial of LB-102 Toward Primary Endpoint

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, has released enrollment performance ...